Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

Ou Sai-Hong Ignatius; Gadgeel Shirish M.; Barlesi Fabrice; Yang James Chih-Hsin; De Petris Luigi; Kim Dong-Wan; Govindan Ramaswamy; Dingemans Anne-Marie; Crino Lucio; Lena Herve; Popat Sanjay; Ahn Jin Seok; Dansin Eric; Mitry Emmanuel; Mueller Barbara; Bordogna Walter; Balas Bogdana; Morcos Peter N.; Shaw Alice T.

首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

【24h】

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

机译：从Alk阳性非小细胞肺癌中粘合来自邻接期II研究（NP28673和NP28761）的总存活和安全数据

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives: A pooled analysis of two open-label phase II studies of alectinib (NP28673 [NCT01801111] and NP28761 [NCT01871805]) demonstrated clinical activity in patients with advanced, anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) previously treated with crizotinib. Longer-term and final pooled analyses of overall survival (OS) and safety data from the two studies are presented here.

机译：目的：对邻接肺炎（NP28673 [NCT018011111]和NP28761 [NCT01871805）的两项开放标签II研究的汇总分析表明了先进的气相生淋巴瘤激酶阳性（ALK +）非小细胞肺癌患者的临床活性（先前用克里齐替尼治疗的NSCLC。这里介绍了总生存（OS）和两项研究的总体生存（OS）和安全数据的长期和最终汇总分析。

著录项

来源
《Lung cancer: Journal of the International Association for the Study of Lung Cancer》 |2020年第1期|共6页
作者
Ou Sai-Hong Ignatius; Gadgeel Shirish M.; Barlesi Fabrice; Yang James Chih-Hsin; De Petris Luigi; Kim Dong-Wan; Govindan Ramaswamy; Dingemans Anne-Marie; Crino Lucio; Lena Herve; Popat Sanjay; Ahn Jin Seok; Dansin Eric; Mitry Emmanuel; Mueller Barbara; Bordogna Walter; Balas Bogdana; Morcos Peter N.; Shaw Alice T.;
展开▼
作者单位

Univ Calif Irvine Chao Family Comprehens Canc Ctr Irvine CA 92717 USA;

Univ Michigan Ann Arbor MI 48109 USA;

Aix Marseille Univ AP HM CRCM INSERM Marseille France;

Natl Taiwan Univ Hosp Taipei Taiwan;

Karolinska Univ Hosp Stockholm Sweden;

Seoul Natl Univ Hosp Seoul South Korea;

Washington Univ Sch Med Alvin J Siteman Canc Ctr St Louis MO USA;

Maastricht Univ Med Ctr Maastricht Netherlands;

IRCCS Ist Sci Romagnolo Studio &

Cura Tumori IRST Meldola Italy;

Hop Pontchaillou Rennes France;

Royal Marsden Hosp London England;

Samsung Med Ctr Seoul South Korea;

Ctr Oscar Lambret Lille France;

F Hoffmann La Roche Ltd Basel Switzerland;

F Hoffmann La Roche Ltd Basel Switzerland;

F Hoffmann La Roche Ltd Basel Switzerland;

F Hoffmann La Roche Ltd Basel Switzerland;

Roche Innovat Ctr New York NY USA;

Massachusetts Gen Hosp Canc Ctr Yawkey 7B 32 Fruit St Boston MA 02114 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Alectinib; ALK; NSCLC; Overall survival; Pooled analysis; Safety;

机译：alectinib;alk;nsclc;整体生存;汇总分析;安全;

相似文献

外文文献
中文文献
专利

1. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer [J] . Ou Sai-Hong Ignatius, Gadgeel Shirish M., Barlesi Fabrice, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2020,第1期

机译：从Alk阳性非小细胞肺癌中粘合来自邻接期II研究（NP28673和NP28761）的总存活和安全数据
2. P3.02a-016 Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC) [J] . James Chih-Hsin Yang, Sai-Hong Ou, Luigi De Petris, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P3.02A-016从Alk +非小细胞肺癌（NSCLC）中的两期II研究（NP28673和NP28761）的粘合疗效和安全数据（NSCLC）
3. P3.02a-016 Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC) [J] . James Chih-Hsin Yang, Sai-Hong Ou, Luigi De Petris, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P3.02A-016从Alk +非小细胞肺癌（NSCLC）中的两期II研究（NP28673和NP28761）的粘合疗效和安全数据（NSCLC）
4. The impact of the type of resection on survival in patients with N1 non-small-cell lung cancers [C] . Umit Aydogmus, Levent Cansever, Yasar Sonmezoglu, 21st international conference on screening for lung cancer . 2009

机译：切除类型对N1非小细胞肺癌患者生存的影响
5. The effectiveness of chemoradiation for stage III non-small-cell lung cancer patients at the Kingston Regional Cancer Center (Ontario). [D] . Sinclair, Suzanne Marie. 2003

机译：金斯敦地区癌症中心（安大略省）对III期非小细胞肺癌患者进行化学放射治疗的有效性。
6. Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies [O] . Shirish Gadgeel, Alice T Shaw, Fabrice Barlesi, 2019

机译：II期NP28673和NP28761阶段接受伊莱替尼治疗的晚期间变性淋巴瘤激酶（ALK）-阳性非小细胞肺癌（NSCLC）患者的反应时间
7. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. [O] . Yang, JC-H, Ou, S-HI, De Petris, L, 2017

机译：来自alectinib的关键性II期研究（Np28673和Np28761）在aLK阳性非小细胞肺癌中的汇总系统功效和安全性数据。

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

摘要

著录项

相似文献

相关主题

期刊订阅